Jason S Metzner

20180229017, Aug 16, 2018

Feb 23, 2018

15/903262

- Irvine CA, US
Michael Augarten - Irvine CA, US
Zachary Dominguez - Santa Barbara CA, US
Ethan Franklin - Goleta CA, US
Edwin J. Kayda - Santa Barbara CA, US
Jason Metzner - Covington WA, US

A61M 37/00
A61L 31/16
A61L 31/14
A61L 31/04

A skin treatment device is provided including bioerodible polymeric microneedles which are designed to more effectively deliver beneficial agents to the skin. The device includes a flexible substrate and an arrangement, for example, an array, of microneedles projecting from the substrate.

20180133401, May 17, 2018

Jan 11, 2018

15/868945

- Irvine CA, US
Mike AUGARTEN - Goleta CA, US
Darin MESSINA - Santa Barbara CA, US
Jason METZNER - Covington WA, US
Ethan FRANKLIN - Goleta CA, US

A61M 5/20
A61M 5/28
C12N 5/077
A61M 3/00
A61M 5/19
A61M 1/00
A61M 5/31

Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction.

20170258617, Sep 14, 2017

May 30, 2017

15/608497

- Austin TX, US
Mitchell H. Babkes - Santa Clarita CA, US
Jason Metzner - Covington WA, US
Zachary P. Dominguez - Santa Barbara CA, US

Apollo Endosurgery US, Inc. - Austin TX

A61F 5/00

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

20160279401, Sep 29, 2016

Mar 27, 2015

14/671690

- Irvine CA, US
Michael Augarten - Irvine CA, US
Zachary Dominguez - Santa Barbara CA, US
Ethan Franklin - Goleta CA, US
Edwin J. Kayda - Santa Barbara CA, US
Jason Metzner - Covington WA, US

A61M 37/00
A61L 31/14
A61L 31/04

A skin treatment device is provided including bioerodible polymeric microneedles which are designed to more effectively deliver beneficial agents to the skin. The device includes a flexible substrate and an arrangement, for example, an array, of microneedles projecting from the substrate.

20150142044, May 21, 2015

Jan 29, 2015

14/608538

- Austin TX, US
Mitchell H. Babkes - Santa Clarita CA, US
Jason Metzner - Covington WA, US
Zachary P. Dominguez - Santa Barbara CA, US

APOLLO ENDOSURGERY, INC. - Austin TX

A61F 5/00

606191

A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, or the greater and lesser curvatures in the middle of the stomach, to stimulate satiety-inducing nerves. Some devices may combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.

20150094753, Apr 2, 2015

Oct 21, 2014

14/519692

- Austin TX, US
Mitchell H. Babkes - Santa Clarita CA, US
Justin Schwab - Santa Barbara CA, US
Christopher S. Mudd - Keller TX, US
Jason Metzner - Covington WA, US

APOLLO ENDOSURGERY, INC. - Austin TX

A61F 5/00

606192, 606198

Transoral obesity treatment devices and related methods for operation thereof are described which occupy space within a stomach and/or stimulate the stomach wall. The transoral obesity treatment devices and related methods are intended to assist a patient in maintaining a healthy body weight. Features of the devices include insertion transorally and without invasive surgery, without associated patient risks of invasive surgery, and without substantial patient discomfort. The life span of these devices may be material-dependent upon long-term survivability within an acidic stomach, but is intended to last one year or longer. The devices have the capacity to vary in size and are desirably self-actuating in that they change shape and/or volume using internal motors or actuators. The changing character of the devices helps prevent the person's stomach from compensating for the implant, such as sometimes happens with static intragastric devices.

20140350517, Nov 27, 2014

May 21, 2014

14/284268

- Irvine CA, US
Tiago Bertolote - Geneve, CH
Ethan Franklin - Goleta CA, US
Justin J. Schwab - Santa Barbara CA, US
Mike Augarten - Goleta CA, US
Jason Metzner - Covington WA, US

Allergan, Inc. - Irvine CA

A61M 5/315
A61M 5/50

604506, 604218, 604189, 604220, 604111

Described are devices and systems for protection of injectable substances such as adipose cells from excessive stress or pressure during injection procedures. Further described are stress control mechanisms for detecting and/or controlling stress or pressure within injection devices.

20140276384, Sep 18, 2014

Mar 11, 2014

14/204796

- Irvine CA, US
Mike Augarten - Goleta CA, US
Darin Messina - Santa Barbara CA, US
Jason Metzner - Covington WA, US
Ethan Franklin - Goleta CA, US

Allergan, Inc. - Irvine CA

A61M 5/168
A61M 5/315

604 82, 604257, 4352831

Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction.